These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 35883026)

  • 1. d-Borneol enhances cisplatin sensitivity via p21/p27-mediated S-phase arrest and cell apoptosis in non-small cell lung cancer cells and a murine xenograft model.
    Li J; Yuan J; Li Y; Wang J; Gong D; Xie Q; Ma R; Wang J; Ren M; Lu D; Xu Z
    Cell Mol Biol Lett; 2022 Jul; 27(1):61. PubMed ID: 35883026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. d-Borneol enhances cisplatin sensitivity via autophagy dependent EMT signaling and NCOA4-mediated ferritinophagy.
    Li J; Yuan J; Li Y; Wang J; Xie Q; Ma R; Wang J; Ren M; Lu D; Xu Z
    Phytomedicine; 2022 Nov; 106():154411. PubMed ID: 36030746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo.
    Jafri SH; Glass J; Shi R; Zhang S; Prince M; Kleiner-Hancock H
    J Exp Clin Cancer Res; 2010 Jul; 29(1):87. PubMed ID: 20594324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.
    Wang LH; Li Y; Yang SN; Wang FY; Hou Y; Cui W; Chen K; Cao Q; Wang S; Zhang TY; Wang ZZ; Xiao W; Yang JY; Wu CF
    Br J Cancer; 2014 Jan; 110(2):341-52. PubMed ID: 24300974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetyl-11-keto-β-boswellic acid enhances the cisplatin sensitivity of non-small cell lung cancer cells through cell cycle arrest, apoptosis induction, and autophagy suppression via p21-dependent signaling pathway.
    Lv M; Zhuang X; Zhang Q; Cheng Y; Wu D; Wang X; Qiao T
    Cell Biol Toxicol; 2021 Apr; 37(2):209-228. PubMed ID: 32562082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS; Zheng YL; Zhao J; Chun X
    Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.
    Ren T; Shan J; Li M; Qing Y; Qian C; Wang G; Li Q; Lu G; Li C; Peng Y; Luo H; Zhang S; Yang Y; Cheng Y; Wang D; Zhou SF
    Drug Des Devel Ther; 2015; 9():2887-910. PubMed ID: 26089640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3.
    Ku JM; Hong SH; Kim HI; Kim MJ; Kim SK; Kim M; Choi SY; Park J; Kim HK; Kim JH; Seo HS; Shin YC; Ko SG
    Phytomedicine; 2020 Jan; 66():153109. PubMed ID: 31790894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC).
    Wang Y; Wu Y; Xie S
    Bioengineered; 2022 Feb; 13(2):3651-3664. PubMed ID: 35230201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo inhibitory effect of the combination of Wenxia Changfu formula [see text] with cisplatin in non-small cell lung cancer.
    Ji XM; Ouyang B; Liu H; Liu GW; Wu ZC; Yu HY; Wang CY; Wang ZX; Wang WP
    Chin J Integr Med; 2011 Dec; 17(12):908-16. PubMed ID: 22139542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
    Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
    Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
    Wang Q; Wu J; Wei H; Huang H; Huang Y; Fang H; Gong X; Sun J; Wu Y; Lei C; Yu J; Hu D
    Int J Biochem Cell Biol; 2021 Sep; 138():106040. PubMed ID: 34246759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels.
    Yan D; Zheng X; Tu L; Jia J; Li Q; Cheng L; Wang X
    Mol Med Rep; 2015 Jan; 11(1):295-302. PubMed ID: 25352209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer.
    Zhong T; Zhang J; Liu X; Li H
    Cell Oncol (Dordr); 2023 Oct; 46(5):1493-1507. PubMed ID: 37219768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways.
    Zhu B; Ren C; Du K; Zhu H; Ai Y; Kang F; Luo Y; Liu W; Wang L; Xu Y; Jiang X; Zhang Y
    Biochem Pharmacol; 2019 Dec; 170():113642. PubMed ID: 31541631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
    Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G
    Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC.
    Hu Y; Hong Y; Xu Y; Liu P; Guo DH; Chen Y
    Apoptosis; 2014 Nov; 19(11):1627-36. PubMed ID: 25213670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.